Trials / Enrolling By Invitation
Enrolling By InvitationNCT07443202
Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
A Randomized, Vehicle-Controlled, Multicenter, Double-Masked, Parallel, Phase 2 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of Lotilaner Ophthalmic Gel in Participants With Ocular Rosacea (KORE)
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (estimated)
- Sponsor
- Tarsus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate lotilaner treatment in patients with ocular rosacea.
Detailed description
To evaluate safety of lotilaner compared to vehicle control in the treatment of ocular rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lotilaner | lotilaner |
| DRUG | Vehicle | Vehicle of lotilaner |
Timeline
- Start date
- 2025-12-05
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2026-03-02
- Last updated
- 2026-03-02
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07443202. Inclusion in this directory is not an endorsement.